Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL29353950 | 1.00 | TSHR (0.46) | — | |
| Pyrimidine SCHEMBL362042 | 1.00 | TSHR (0.46) | — | |
| Pyrimidine SCHEMBL8141450 | 1.00 | — | — | |
| Pyrimidine SCHEMBL28088036 | 1.00 | TSHR (0.46) | — | |
| Pyrimidine SCHEMBL6054190 | 1.00 | TSHR (0.46) | — | |
| Pyrimidine SCHEMBL692916 | 1.00 | — | — | |
| Pyrimidine SCHEMBL5772335 | 0.95 | — | — | |
| Pyrimidine SCHEMBL9658334 | 0.95 | — | — | |
| Pyrimidine SCHEMBL27688482 | 0.95 | — | — | |
| Pyrimidine SCHEMBL27654821 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115317489-A | Application of BML-275 in preparation of dormant polyploid giant tumor cell inhibitor | 南通大学附属医院 | 2022-11-11 | — | — | CN | claimed |
| CN-108807712-A | A kind of novel OLED top illuminating devices and display device | 上海钥熠电子科技有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-108473962-A | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2018-08-31 | — | — | CN | claimed |
| CN-104507939-B | tetrahydropyrazolopyrimidine compounds | 卫材R&D管理有限公司 | 2017-07-25 | — | — | CN | claimed |
| CN-104507939-A | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MAN CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-102083835-A | Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof | WYETH CORP | 2011-06-01 | — | — | CN | claimed |
| CN-1202087-C | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments | ESTEVE LABOR DR (ES) | 2005-05-18 | — | — | CN | claimed |
| CN-1509291-A | Oxazolo-and-furopyrimidines and their use in medicaments against tumors | ��˹��ŵ�� | 2004-06-30 | — | — | CN | claimed |
| CN-1268124-A | Acyl-piperazinyl-pyrimidine derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2000-09-27 | — | — | CN | claimed |
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-118076598-A | Pyrimidinyl triazole compound or salt thereof, and pest control agent and pest control method each containing the same as active ingredient | 日本农药株式会社 | 2024-05-24 | — | — | CN | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-1173132-A | Dihydropyrimidine compounds and application thereof | SYNAPTIC PHARMACEUTIC CORP (US) | 1998-02-11 | — | — | CN | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| CN-1075965-A | New Hete rocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-09-08 | — | — | CN | disclosed |
| CN-1070404-A | New Hete rocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-03-31 | — | — | CN | disclosed |
| CN-1059908-A | Pyrimidine derivatives and medicine thereof | NIPPON SHINYAKU CO LTD (JP) | 1992-04-01 | — | — | CN | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |